Zongertinib in HER2-altered breast cancer: Preclinical activity and preliminary results from a phase Ia dose-escalation study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

Knowing the location of a gene within intact tissue or a single cell allows scientists to unlock unknown cellular functions. This information is often lost in most genetic sequencing techniques, but ...

Outcomes in patients (pts) younger than 50 years old (yo) with treatment-naïve blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG): Subanalysis of a phase 1/2 trial.